Cost-effectiveness of adding oseltamivir to primary care for influenza-like-illness: economic evaluation alongside the randomised controlled ALIC4E trial in 15 European countries

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Cost-effectiveness of adding oseltamivir to primary care for influenza-like-illness : economic evaluation alongside the randomised controlled ALIC4E trial in 15 European countries. / Li, Xiao; Bilcke, Joke; van der Velden, Alike W.; Bruyndonckx, Robin; Coenen, Samuel; Bongard, Emily; de Paor, Muirrean; Chlabicz, Slawomir; Godycki-Cwirko, Maciek; Francis, Nick; Aabenhus, Rune; Bucher, Heiner C.; Colliers, Annelies; De Sutter, An; Garcia-Sangenis, Ana; Glinz, Dominik; Harbin, Nicolay J.; Kosiek, Katarzyna; Lindbaek, Morten; Lionis, Christos; Llor, Carl; Miko-Pauer, Reka; Jurgute, Ruta Radzeviciene; Seifert, Bohumil; Sundvall, Par-Daniel; Lundgren, Pia Touboul; Tsakountakis, Nikolaos; Verheij, Theo J.; Goossens, Herman; Butler, Christopher C.; Beutels, Philippe; ALIC4Etrial Investigators.

I: European Journal of Health Economics, Bind 24, 2023.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Li, X, Bilcke, J, van der Velden, AW, Bruyndonckx, R, Coenen, S, Bongard, E, de Paor, M, Chlabicz, S, Godycki-Cwirko, M, Francis, N, Aabenhus, R, Bucher, HC, Colliers, A, De Sutter, A, Garcia-Sangenis, A, Glinz, D, Harbin, NJ, Kosiek, K, Lindbaek, M, Lionis, C, Llor, C, Miko-Pauer, R, Jurgute, RR, Seifert, B, Sundvall, P-D, Lundgren, PT, Tsakountakis, N, Verheij, TJ, Goossens, H, Butler, CC, Beutels, P & ALIC4Etrial Investigators 2023, 'Cost-effectiveness of adding oseltamivir to primary care for influenza-like-illness: economic evaluation alongside the randomised controlled ALIC4E trial in 15 European countries', European Journal of Health Economics, bind 24. https://doi.org/10.1007/s10198-022-01521-2

APA

Li, X., Bilcke, J., van der Velden, A. W., Bruyndonckx, R., Coenen, S., Bongard, E., de Paor, M., Chlabicz, S., Godycki-Cwirko, M., Francis, N., Aabenhus, R., Bucher, H. C., Colliers, A., De Sutter, A., Garcia-Sangenis, A., Glinz, D., Harbin, N. J., Kosiek, K., Lindbaek, M., ... ALIC4Etrial Investigators (2023). Cost-effectiveness of adding oseltamivir to primary care for influenza-like-illness: economic evaluation alongside the randomised controlled ALIC4E trial in 15 European countries. European Journal of Health Economics, 24. https://doi.org/10.1007/s10198-022-01521-2

Vancouver

Li X, Bilcke J, van der Velden AW, Bruyndonckx R, Coenen S, Bongard E o.a. Cost-effectiveness of adding oseltamivir to primary care for influenza-like-illness: economic evaluation alongside the randomised controlled ALIC4E trial in 15 European countries. European Journal of Health Economics. 2023;24. https://doi.org/10.1007/s10198-022-01521-2

Author

Li, Xiao ; Bilcke, Joke ; van der Velden, Alike W. ; Bruyndonckx, Robin ; Coenen, Samuel ; Bongard, Emily ; de Paor, Muirrean ; Chlabicz, Slawomir ; Godycki-Cwirko, Maciek ; Francis, Nick ; Aabenhus, Rune ; Bucher, Heiner C. ; Colliers, Annelies ; De Sutter, An ; Garcia-Sangenis, Ana ; Glinz, Dominik ; Harbin, Nicolay J. ; Kosiek, Katarzyna ; Lindbaek, Morten ; Lionis, Christos ; Llor, Carl ; Miko-Pauer, Reka ; Jurgute, Ruta Radzeviciene ; Seifert, Bohumil ; Sundvall, Par-Daniel ; Lundgren, Pia Touboul ; Tsakountakis, Nikolaos ; Verheij, Theo J. ; Goossens, Herman ; Butler, Christopher C. ; Beutels, Philippe ; ALIC4Etrial Investigators. / Cost-effectiveness of adding oseltamivir to primary care for influenza-like-illness : economic evaluation alongside the randomised controlled ALIC4E trial in 15 European countries. I: European Journal of Health Economics. 2023 ; Bind 24.

Bibtex

@article{9635d1962ad24c388dae6cdc3f07e7b4,
title = "Cost-effectiveness of adding oseltamivir to primary care for influenza-like-illness: economic evaluation alongside the randomised controlled ALIC4E trial in 15 European countries",
abstract = "Background Oseltamivir is usually not often prescribed (or reimbursed) for non-high-risk patients consulting for influenza-like-illness (ILI) in primary care in Europe. We aimed to evaluate the cost-effectiveness of adding oseltamivir to usual primary care in adults/adolescents (13 years +) and children with ILI during seasonal influenza epidemics, using data collected in an open-label, multi-season, randomised controlled trial of oseltamivir in 15 European countries. Methods Direct and indirect cost estimates were based on patient reported resource use and official country-specific unit costs. Health-Related Quality of Life was assessed by EQ-5D questionnaires. Costs and quality adjusted life-years (QALY) were bootstrapped (N = 10,000) to estimate incremental cost-effectiveness ratios (ICER), from both the healthcare payers' and the societal perspectives, with uncertainty expressed through probabilistic sensitivity analysis and expected value for perfect information (EVPI) analysis. Additionally, scenario (self-reported spending), comorbidities subgroup and country-specific analyses were performed. Results The healthcare payers' expected ICERs of oseltamivir were euro22,459 per QALY gained in adults/adolescents and euro13,001 in children. From the societal perspective, oseltamivir was cost-saving in adults/adolescents, but the ICER is euro8,344 in children. Large uncertainties were observed in subgroups with comorbidities, especially for children. The expected ICERs and extent of decision uncertainty varied between countries (EVPI ranged euro1-euro35 per patient). Conclusion Adding oseltamivir to primary usual care in Europe is likely to be cost-effective for treating adults/adolescents and children with ILI from the healthcare payers' perspective (if willingness-to-pay per QALY gained > euro22,459) and cost-saving in adults/adolescents from a societal perspective.",
keywords = "Tamiflu, Cost-utility analysis, Europe, Multi-country, QALY, ILI, Direct cost, Indirect cost, Productivity losses, ADULTS, METAANALYSIS",
author = "Xiao Li and Joke Bilcke and {van der Velden}, {Alike W.} and Robin Bruyndonckx and Samuel Coenen and Emily Bongard and {de Paor}, Muirrean and Slawomir Chlabicz and Maciek Godycki-Cwirko and Nick Francis and Rune Aabenhus and Bucher, {Heiner C.} and Annelies Colliers and {De Sutter}, An and Ana Garcia-Sangenis and Dominik Glinz and Harbin, {Nicolay J.} and Katarzyna Kosiek and Morten Lindbaek and Christos Lionis and Carl Llor and Reka Miko-Pauer and Jurgute, {Ruta Radzeviciene} and Bohumil Seifert and Par-Daniel Sundvall and Lundgren, {Pia Touboul} and Nikolaos Tsakountakis and Verheij, {Theo J.} and Herman Goossens and Butler, {Christopher C.} and Philippe Beutels and {ALIC4Etrial Investigators}",
year = "2023",
doi = "10.1007/s10198-022-01521-2",
language = "English",
volume = "24",
journal = "European Journal of Health Economics",
issn = "1618-7598",
publisher = "Springer",

}

RIS

TY - JOUR

T1 - Cost-effectiveness of adding oseltamivir to primary care for influenza-like-illness

T2 - economic evaluation alongside the randomised controlled ALIC4E trial in 15 European countries

AU - Li, Xiao

AU - Bilcke, Joke

AU - van der Velden, Alike W.

AU - Bruyndonckx, Robin

AU - Coenen, Samuel

AU - Bongard, Emily

AU - de Paor, Muirrean

AU - Chlabicz, Slawomir

AU - Godycki-Cwirko, Maciek

AU - Francis, Nick

AU - Aabenhus, Rune

AU - Bucher, Heiner C.

AU - Colliers, Annelies

AU - De Sutter, An

AU - Garcia-Sangenis, Ana

AU - Glinz, Dominik

AU - Harbin, Nicolay J.

AU - Kosiek, Katarzyna

AU - Lindbaek, Morten

AU - Lionis, Christos

AU - Llor, Carl

AU - Miko-Pauer, Reka

AU - Jurgute, Ruta Radzeviciene

AU - Seifert, Bohumil

AU - Sundvall, Par-Daniel

AU - Lundgren, Pia Touboul

AU - Tsakountakis, Nikolaos

AU - Verheij, Theo J.

AU - Goossens, Herman

AU - Butler, Christopher C.

AU - Beutels, Philippe

AU - ALIC4Etrial Investigators

PY - 2023

Y1 - 2023

N2 - Background Oseltamivir is usually not often prescribed (or reimbursed) for non-high-risk patients consulting for influenza-like-illness (ILI) in primary care in Europe. We aimed to evaluate the cost-effectiveness of adding oseltamivir to usual primary care in adults/adolescents (13 years +) and children with ILI during seasonal influenza epidemics, using data collected in an open-label, multi-season, randomised controlled trial of oseltamivir in 15 European countries. Methods Direct and indirect cost estimates were based on patient reported resource use and official country-specific unit costs. Health-Related Quality of Life was assessed by EQ-5D questionnaires. Costs and quality adjusted life-years (QALY) were bootstrapped (N = 10,000) to estimate incremental cost-effectiveness ratios (ICER), from both the healthcare payers' and the societal perspectives, with uncertainty expressed through probabilistic sensitivity analysis and expected value for perfect information (EVPI) analysis. Additionally, scenario (self-reported spending), comorbidities subgroup and country-specific analyses were performed. Results The healthcare payers' expected ICERs of oseltamivir were euro22,459 per QALY gained in adults/adolescents and euro13,001 in children. From the societal perspective, oseltamivir was cost-saving in adults/adolescents, but the ICER is euro8,344 in children. Large uncertainties were observed in subgroups with comorbidities, especially for children. The expected ICERs and extent of decision uncertainty varied between countries (EVPI ranged euro1-euro35 per patient). Conclusion Adding oseltamivir to primary usual care in Europe is likely to be cost-effective for treating adults/adolescents and children with ILI from the healthcare payers' perspective (if willingness-to-pay per QALY gained > euro22,459) and cost-saving in adults/adolescents from a societal perspective.

AB - Background Oseltamivir is usually not often prescribed (or reimbursed) for non-high-risk patients consulting for influenza-like-illness (ILI) in primary care in Europe. We aimed to evaluate the cost-effectiveness of adding oseltamivir to usual primary care in adults/adolescents (13 years +) and children with ILI during seasonal influenza epidemics, using data collected in an open-label, multi-season, randomised controlled trial of oseltamivir in 15 European countries. Methods Direct and indirect cost estimates were based on patient reported resource use and official country-specific unit costs. Health-Related Quality of Life was assessed by EQ-5D questionnaires. Costs and quality adjusted life-years (QALY) were bootstrapped (N = 10,000) to estimate incremental cost-effectiveness ratios (ICER), from both the healthcare payers' and the societal perspectives, with uncertainty expressed through probabilistic sensitivity analysis and expected value for perfect information (EVPI) analysis. Additionally, scenario (self-reported spending), comorbidities subgroup and country-specific analyses were performed. Results The healthcare payers' expected ICERs of oseltamivir were euro22,459 per QALY gained in adults/adolescents and euro13,001 in children. From the societal perspective, oseltamivir was cost-saving in adults/adolescents, but the ICER is euro8,344 in children. Large uncertainties were observed in subgroups with comorbidities, especially for children. The expected ICERs and extent of decision uncertainty varied between countries (EVPI ranged euro1-euro35 per patient). Conclusion Adding oseltamivir to primary usual care in Europe is likely to be cost-effective for treating adults/adolescents and children with ILI from the healthcare payers' perspective (if willingness-to-pay per QALY gained > euro22,459) and cost-saving in adults/adolescents from a societal perspective.

KW - Tamiflu

KW - Cost-utility analysis

KW - Europe

KW - Multi-country

KW - QALY

KW - ILI

KW - Direct cost

KW - Indirect cost

KW - Productivity losses

KW - ADULTS

KW - METAANALYSIS

U2 - 10.1007/s10198-022-01521-2

DO - 10.1007/s10198-022-01521-2

M3 - Journal article

C2 - 36131214

VL - 24

JO - European Journal of Health Economics

JF - European Journal of Health Economics

SN - 1618-7598

ER -

ID: 321115687